← Russell 3000 cross-section

GRAL GRAIL, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$3.7bn
Revenue TTM
$165m
Net income TTM
$-392m
Free cash flow
$-296m
Composite score
Sector rank
#1264

Valuation

P / E
EV / EBITDA
EV / sales
22.3
FCF yield
-7.91%
Earnings yield vs 10-yr
-15.19pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-236.9%
EBITDA margin
-248.4%
ROE
-15.4%
ROIC
-22.5%
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.09m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue generated from customers with negotiated contractual rates, or with rebates or discounts, is generally lower margin as compared to revenue generated based on list pricing. These seasonal trends have caused, and will likely continue to cause, fluctuations in our quarterly results, including fluctuations in sequential revenue growth rates. “Risk Factors” for more information. Components of Results of Operations Screening Revenue We currently derive screening revenue through the sale of Galleri primarily within the United States and primarily through primary care physicians, health systems, employers, digital health platforms, payors, and life insurance providers. …GRAIL, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →